ChiCTR2000040520 版本V1.1 版本创建时间2021/03/07 22:01:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000040520 

最近更新日期:

Date of Last Refreshed on:

2021-03-07 21:49:46 

注册时间:

Date of Registration:

2020-12-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

乌灵胶囊治疗青少年轻中度抑郁、焦虑状态的临床研究

Public title:

Effect of Wuling caspule on adolescent with mild to moderate anxiety and depression state

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乌灵胶囊治疗青少年轻中度抑郁、焦虑状态的临床研究

Scientific title:

Effect of Wuling caspule on adolescent with mild to moderate anxiety and depression state

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2000004122

申请注册联系人:

方妍彤 

研究负责人:

骆宏 

Applicant:

Fang Yantong 

Study leader:

Luo Hong 

申请注册联系人电话:

Applicant telephone:

+86 15958018854

研究负责人电话:

Study leader's telephone:

+86 15958018854

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

342474501@qq.com

研究负责人电子邮件:

Study leader's E-mail:

luohong@hzun.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

杭州市拱宸桥温州路126号

研究负责人通讯地址:

杭州市拱宸桥温州路126号

Applicant address:

126 Wenzhou Road, Gongchenqiao, Hangzhou, Zheliang, China

Study leader's address:

126 Wenzhou Road, Gongchenqiao, Hangzhou, Zheliang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

杭州师范大学附属医院

Applicant's institution:

The Affiliated Hospital of Hangzhou Normal University

研究负责人所在单位:

杭州师范大学附属医院

Affiliation of the Leader:

The Affiliated Hospital of Hangzhou Normal University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020(E2)-KS-012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

杭州师范大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Affiliated Hospital of Hangzhou Normal University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

干文韬

Contact Name of the ethic committee:

Gan Wentao

伦理委员会联系地址:

杭州市拱宸桥温州路126号

Contact Address of the ethic committee:

126 Wenzhou Road, Gongchenqiao, Hangzhou, Zheliang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

杭州师范大学附属医院

Primary sponsor:

The Affiliated Hospital of Hangzhou Normal University

研究实施负责(组长)单位地址:

杭州市拱宸桥温州路126号

Primary sponsor's address:

126 Wenzhou Road, Gongchenqiao, Hangzhou, Zheliang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

杭州师范大学附属医院

具体地址:

杭州市拱宸桥温州路126号

Institution
hospital:

Huzhou Hospital of Traditional Chinese Medici

Address:

126 Wenzhou Road, Gongchenqiao, Hangzhou

经费或物资来源:

浙江佐力药业股份有限公司

Source(s) of funding:

Zhejiang Jolly Pharmaceutical Co., Ltd.

Target disease:

Mild to moderate anxiety and depression

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1)通过前瞻性队列研究探讨乌灵胶囊对青少年轻中度抑郁、焦虑状态的临床疗效 (2)通过前瞻性队列研究探讨乌灵胶囊对青少年睡眠的改善效果  

Objectives of Study:

(1)By prospective cohort study was to investigate the wu ling capsule on the clinical curative effect of adolescent mild-to-moderate , state (2)By prospective cohort study was to investigate the wu ling capsule for adolescents to improve the effect of sleep

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄:8-17 岁;性别不限;
(2)符合 DSM-5 中抑郁障碍或焦虑障碍的诊断标准;
(3)汉密尔顿抑郁量表(HAMD-17)>17 或者汉密尔顿焦虑量表(HAMA-14)>14;
(4)实施心理干预治疗;
(5)受试者及其监护人愿意签署知情同意书参加本研究

Inclusion criteria

(1) age: 8 to 17 years old;Gender not limited;
(2) Accord with the DSM - 5 diagnostic criteria for or disorder
(3)Hamilton rating scale (HAMD - 17) > 17 or Hamilton scale (HAMA - 14) > 14
(4)Implement the psychological intervention treatment
(5)The subjects and their guardians willing to sign a consent form to participate in this study

排除标准:

(1)汉密尔顿抑郁量表(HAMD-17)>24 或者汉密尔顿焦虑量表(HAMA-14)>29
(2)有明显自杀倾向;
(3)精神发育迟滞、精神分裂症、癫痫史等神经精神病性障碍;
(4)头部创伤史(失去意识超过 10 分钟)、其他不稳定重大躯体疾病或可造成精神
症状的躯体疾病;
(5)可疑精神发育迟滞者;
(6)入组前有酒精或物质滥用史

Exclusion criteria:

(1) the Hamilton rating scale (HAMD - 17) > 24 or the Hamilton scale (HAMA - 14) > 29
(2) Have obvious suicide;
(3) Mental retardation, history of neuropsychiatric disorders such as schizophrenia, epilepsy;
(4) Head trauma history (losing consciousness more than 10 minutes), the instability of other major body disease or mental symptoms caused by the body
(5) Suspected mental retardation;
(6)The group has a history of alcohol or substance abuse

研究实施时间:

Study execute time:

From 2020-12-31 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-12-31 00:00:00 To 2021-06-30 00:00:00  

干预措施:

Interventions:

组别:

暴露组

样本量:

35

Group:

Exposed group

Sample size:

干预措施:

心理干预联合乌灵胶囊

干预措施代码:

Intervention:

psychotherapy+Wuling capsule

Intervention code:

组别:

非暴露组

样本量:

35

Group:

Non-exposed group

Sample size:

干预措施:

心理干预

干预措施代码:

Intervention:

psychotherapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

杭州师范大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Huzhou Hospital of Traditional Chinese Medici

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

汉密尔顿抑郁量表-17

指标类型:

主要指标

Outcome:

Hamilton Depression Scale-17 items

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表-14

指标类型:

主要指标

Outcome:

Hamilton Anxiety Scale -14

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童抑郁障碍自评量表

指标类型:

次要指标

Outcome:

Self-rating Scale for Depression in Children

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

儿童焦虑性情绪障碍筛查量表

指标类型:

次要指标

Outcome:

Screening Scale for Anxiety disorders in children

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsberg Sleep Quality Index,

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 17 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究属于前瞻性队列研究,未涉及随机方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a prospective cohort study and does not involve random methods.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本网络平台 http://www.chictr.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.chictr.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表及自建数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and an electronic data capture: Case Record Form and database

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2020-12-01 06:52:10